Articles

Podcasts

Videos

Clinical

Out of 102 monoclonal antibodies tested, only Cv2.1169 and Cv2.3194 cross-neutralized all variants of concern, including Omicron BA.1 and BA.2 subvariants.

2 Different COVID-19 Monoclonal Antibodies Effectively Neutralize Omicron 

The FDA VRBPAC votes to recommend mRNA vaccines in youngest children; WHO moves to rename monkeypox; Anthony Fauci is diagnosed with COVID-19; and Pfizer stops recruiting for a Paxlovid trial.

Infectious Disease Update: June 15, 2022

Today, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend both the Moderna and Pfizer-BioNTech COVID-19 vaccines for children as young as 6 months old.

FDA Vaccine Advisory Committee Recommends Moderna and Pfizer-BioNTech Vaccines for Everyone 6 Months and Older

High vaccination rates at Cornell University prevented severe disease during the Omicron surge of the COVID-19 pandemic but didn’t stop the rapid spread of the virus, even with comprehensive public health measures.

Routine Surveillance Details Rapid Spread of COVID-19 at Cornell University During Omicron Surge

The first report from WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) concedes SARS-CoV-2 source remains a mystery.

WHO Report: Origin of COVID-19 Remains to be Determined

The committee voted twice splitting the questions into younger children (6-11 years) and adolescent (12-17 years) cohorts due to different vaccine dosing amounts. 

FDA VRBPAC Votes to Recommend Moderna COVID-19 Vaccine in Children and Adolescents 6 Years Through 17 Years  

Aethlon Medical’s proprietary Hemopurifier is being studied to treat COVID-19, and they recently reported results.  

A Novel Device With COVID-19 Treatment Potential  

Sanofi and GSK’s booster vaccine candidate is modeled on the Beta COVID-19 variant, and increases Omicron-neutralizing antibody titers 40-fold.

Sanofi-GSK COVID-19 Booster More Protective Against Omicron Than Pfizer-BioNTech

Rather than developing vaccines for each new variant, some officials are pushing to follow the flu vaccine model, with annual vaccination.

As Omicron Spreads, Public Health Officials Ponder When to Update COVID-19 Vaccine

Merck’s antiviral drug molnupiravir may benefit nonhospitalized patients with mild or moderate COVID-19, according to a secondary analysis of phase 3 clinical trial data.



CORONAVIRUS

Latest News